But what makes it amazing is the investor deck and website will still say “in talks with fda on phase 3 approval”.

$EDSA Ruxolitinib (Opzelura) approved by FDA last year seems like a very solid drug for curing vitiligo and is generating tremendous revenue to Incyte.

FDA was pleased with their results and understands HC is moving forward.

* granted FDA fast track status late Dec 2022 * 75% of drugs given Fast Track get approved * ARDS current has limited treatment options, could make a big impact * CEO has sold two previous biotech companies to bigger players Let’s get it 😍🎊💥🆙✅

Fast Tracked FDA status on a drug with no competition.

It looks like EB05 is gonna be that home run, with FDA ‘Fast Track’ designation at the end of Dec 2022, we’re almost at the finish line.

FDA mulling over Emergency use right now I bet Holding strong. .

but to PR the positive review and approval They did exactly that with Fast Track, and also Compassionate Use BOTH APPROVED BY FDA!

A 300% gain in less than a month - and this time sis has plenty of cash in the tank to keep on running to the FDA green light.

$SLS my vote is get GPS green lighted for FDA approval and ramp this company up for M&A. GPS and GFH009 are high potential assets

Really is a great set up here - Get the FDA Green light and collect $50M plus another $25M warrants at $5.40.

$SLS In addition to GPs FDA approval for AML secondary Remission patients - Gps + Keytruda/Checkpoint Inhibition is also best in class for Ovarian cancer patients.

- Gps FDA Approval only a matter of time and is worth $8B in Market Value to Big Pharma - SlS current market cap of $.067B Best Short term investment any of us will find for a long. time.

Great Set Up here - $25M total incoming in Q1/2, Then another $50M when Gps gets the FDA green light - usually that is when small bios need to raise cash, and shorts can cover -- Ange Has them Over a barrel.

I think the share price will be climbing all along the approach to the FDA green light.

2,500% to 5,000% Upside in this ahead of the Fda Green light for Gps, as the first immunotherapy to treat 20,000 AML remission patients.

His 25-year experience, with global drug/biologics approvals and Breakthrough Therapy Designation with FDA, will be of immense value to our organization, especially as 2023 will be a pivotal year for our Company - welcome Andrew!

trial news by EOM + FDA fast tracked + listing extension = we're lookin good!

Insiders buying, catalyst coming, 125 patents, FDA fast track approval, 5 different trials (all positive), grants will help support vs massive dilution.

So close to the finish line with their first opiod substitute (keep in mind they already have fast track approval with FDA).

Good luck bulls…i like the product and fast track designation - the opioid crisis is going to be addressed this year and the fda is working closely with management…im holding and loading these dips too.

Currently targeting pain relief and secured FDA fast track approval!! !

$RSLS nice move, expecting $ENSC to be next big move on good FDA news regarding abuse and tamper resistant opioids for pain relief

good news coming , FDA approval is very near https://twitter.com/ensyscebio/status/1600124924999483394

$ENSC Positive Earning FDA Positive Topline Extended Release Product Low Float. BULLISH.

$ENSC shares and ENSCW warrants because always new good news "As a result of the FDA guidance, we now intend to initially pursue clinical development of PF614 for an acute pain indication while continuing with our chronic pain development pathway.